In the airways of patients with mild allergic asthma, omalizumab reduces Fc epsilon RI+ and IgE+ cells and causes a profound reduction in tissue eosinophilia, together with reductions in submucosal T-cell and B-cell numbers. The gene discussed is IGHE; the disease is Increased total eosinophil count.